Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Tricohepatoenteric syndrome is a rare genetic disorder caused by mutations in or . An upregulation of type 1 interferon signaling is associated with the variation. Introduction of Baricitinib as a JAK1/ 2 kinase inhibitor alongside traditional immunosuppressive agents successfully reduced the symptoms of enteritis by blocking the inflammogenic effects of type 1 interferonopathy in a case of tricohepatoenteric syndrome diagnosed in a 5-year-old boy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158382 | PMC |
| http://dx.doi.org/10.1097/PG9.0000000000000264 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of Enteritis Associated With Tricohepatoenteric Syndrome due to Mutation Using the Combination of JAK1/2 Inhibition and Azathioprine.
JPGN Rep
November 2022
Cellular and Molecular Medicine, University of Bristol, UK.
Tricohepatoenteric syndrome is a rare genetic disorder caused by mutations in or . An upregulation of type 1 interferon signaling is associated with the variation. Introduction of Baricitinib as a JAK1/ 2 kinase inhibitor alongside traditional immunosuppressive agents successfully reduced the symptoms of enteritis by blocking the inflammogenic effects of type 1 interferonopathy in a case of tricohepatoenteric syndrome diagnosed in a 5-year-old boy.
View Article and Find Full Text PDFA combination of mutations in AKR1D1 and SKIV2L in a family with severe infantile liver disease.
Orphanet J Rare Dis
May 2013
Department of Medical and Molecular Genetics and Centre for Rare Diseases and Personalised Medicine, University of Birmingham School of Medicine, Birmingham, UK.
Infantile cholestatic diseases can be caused by mutations in a number of genes involved in different hepatocyte molecular pathways. Whilst some of the essential pathways have a well understood function, such as bile biosynthesis and transport, the role of the others is not known. Here we report the findings of a clinical, biochemical and molecular study of a family with three patients affected with a severe infantile cholestatic disease.
View Article and Find Full Text PDF